

ASX:NRT

NASDAQ:NVGN

Novogen Ltd
(Company)

ABN 37 063 259 754

Capital Structure

Ordinary Shares on
issue:

246 M

Board of Directors

Dr Graham Kelly
Chairman &
Executive Director

Steve Coffey
Non Executive Director

John O'Connor
Non Executive Director

Prof Peter Gunning
Non Executive Director

ASX RELEASE

2 February 2015

Novogen to present at BIO & CEO Investor Conference 9th & 10th February, 2015

New York, NY: Novogen Limited (ASX:NRT; NASDAQ:NVGN) is pleased to announce that Novogen Group CEO and Executive Chairman, Graham Kelly PhD, will be presenting at the 17th annual BIO CEO and Investor Conference being held on the 9th & 10th February, 2015.

The conference is the largest of its kind, focusing on established and emerging publicly listed biotech companies and is attended by a mix of investors, analysts, investment bankers and industry.

Dr Kelly will outline the Company's two proprietary drug technology platforms and their potential therapeutic value in oncology, as well as reviewing the Company's clinical strategy and timetable and anticipated milestones.

Kelly, said, "The BIO CEO and Investor conference presents an opportunity for Novogen to bring its unique story to the attention of the market. Novogen is different. The path we have chosen to take is different because current standard and experimental approaches are failing to address the causes of cancer recurrence: the impregnability of the cancer stem cell and the ability of a cancer to survive by continuing to mutate and produce means of beating new therapies."

"With one technology platform with a potent ability to kill cancer stem cells and a second platform that produces dramatic synergy of some of the most widely used and effective cytotoxics in chemotherapy, we believe we have the potential to make meaningful differences to the lives of patients with malignant cancers."

Date & Time: 9th February, 2015, 9am

Venue: The Waldorf Astoria, New York,
4th Floor, Duke of Windsor Room

About the Bio CEO & Investor Conference

The 17th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. The 2014 CEO & Investor Conference featured 1,820 partnering meetings, 149 company presentations, and 1,400 attendees, over half of which were investors.

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT – based joint venture company, CanTx Inc., with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our websites www.novogen.com

For more information please contact:

Corporate Contact

Dr. Graham Kelly
Executive Chairman & CEO
Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2 9472 4100

Media Enquiries

Cristyn Humphreys
Chief Operating Officer
Novogen Group
Cristyn.Humphreys@novogen.com
+61 (0) 2 9472 4111

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "appear," "intends," "hopes," "anticipates," "believes," "could," "should," "would," "may," "target," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to events that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to the Company's two proprietary technology platforms, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factors including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

